![//imrorwxhnlprli5q.ldycdn.com/cloud/jnBpqKkrllSRikiijlioin/2778223-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/jnBpqKkrllSRikiijlioin/2778223-60-60.gif) | Cas No. 2778223-52-0, Cyclohexanecarboxylic acid, 1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]-, cis- | Pralsetinib | 4/3/2039 (Pralsetinib) | View detail » | 2022 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lrBpqKkrllSRokoqlojpip/171290-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lrBpqKkrllSRokoqlojpip/171290-60-60.gif) | CAS No.171290-52-1, Futibatinib Intermediate | Futibatinib | 11/05/2039 (Futibatinib) | View detail » | 2023 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lnBpqKkrllSRokkqomijiq/109431-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lnBpqKkrllSRokkqomijiq/109431-60-60.gif) | CAS No.109431-87-0, Futibatinib Intermediate | Futibatinib | 11/05/2039 (Futibatinib) | View detail » | 2020 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokoqiqpriq/151266-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokoqiqpriq/151266-60-60.gif) | CAS No.151266-23-8, Futibatinib Intermediate | Futibatinib | 11/05/2039 (Futibatinib) | View detail » | 2017 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lrBpqKkrllSRokqkoikkiq/6228-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lrBpqKkrllSRokqkoikkiq/6228-60-60.gif) | CAS No. 6228-73-5, Deucravacitinib intermediate | Deucravacitinib | 11/7/2033 (Deucravacitinib) | View detail » | |
![//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokokimmiiq/1352925-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokokimmiiq/1352925-60-60.gif) | CAS No. 1352925-63-3, Deucravacitinib intermediate | Deucravacitinib | 11/7/2033 (Deucravacitinib) | View detail » | 2023 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokqkirknio/372118-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokqkirknio/372118-60-60.gif) | CAS No. 372118-00-8, Deucravacitinib intermediate | Deucravacitinib | 11/7/2033 (Deucravacitinib) | View detail » | 2022 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lqBpqKkrllSRokokjpqliq/1609393-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lqBpqKkrllSRokokjpqliq/1609393-60-60.gif) | CAS No. 1609393-89-6, Deucravacitinib intermediate | Deucravacitinib | 11/7/2033 (Deucravacitinib) | View detail » | 2023 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokqkprqliq/679406-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRokqkprqliq/679406-60-60.gif) | CAS No. 679406-03-2, Deucravacitinib intermediate | Deucravacitinib | 11/7/2033 (Deucravacitinib) | View detail » | |
![//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRoklkirriin/1609394-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRoklkirriin/1609394-60-60.gif) | CAS No. 1609394-10-6, Deucravacitinib intermediate | Deucravacitinib | 11/7/2033 (Deucravacitinib) | View detail » | 2023 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lpBpqKkrllSRokokopmmip/7436-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lpBpqKkrllSRokokopmmip/7436-60-60.gif) | CAS No. 7436-22-8, Deuterium source | Deucravacitinib | 11/7/2033 (Deucravacitinib) | View detail » | 2018 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRkkkokijqio/Sotorasib-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/loBpqKkrllSRkkkokijqio/Sotorasib-60-60.gif) | Cas No. 2296729-00-3, Sotorasib | Sotorasib | 9/15/2040 (Sotorasib) | View detail » | |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lqBpqKkrllSRlkiqpqnliq/1346623-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lqBpqKkrllSRlkiqpqnliq/1346623-60-60.gif) | CAS No. 1346623-11-7 | Avacopan | 5/29/2041 (Avacopan) | View detail » | 2023 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lnBpqKkrllSRlkiqjmjmiq/1357259-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lnBpqKkrllSRlkiqjmjmiq/1357259-60-60.gif) | CAS No. 1357259-88-1 | Avacopan | 5/29/2041 (Avacopan) | View detail » | 2019 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lkBpqKkrllSRlkiqlmkliq/838-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lkBpqKkrllSRlkiqlmkliq/838-60-60.gif) | CAS No. 838-57-3, ethyl 3-(4-nitrophenyl)-3-oxopropanoate | Avacopan | 5/29/2041 (Avacopan) | View detail » | 2020 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/ljBpqKkrllSRpjomqionip/3680-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/ljBpqKkrllSRpjomqionip/3680-60-60.gif) | Cas No. 3680-69-1, 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine | Ruxolitinib, Tofacitinib, Ritlecitinib, Baricitinib, Abrocitinib, Delgocitinib | 5/5/2041 (Ruxolitinib); 3/14/2034 (Tofacitinib); 12/3/2034 (Ritlecitinib); 11/30/2032 (Baricitinib); 2/19/2034 (Abrocitinib) | View detail » | 2016 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lrBpqKkrllSRlkknommkip/1146629-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lrBpqKkrllSRlkknommkip/1146629-60-60.gif) | CAS No. 1146629-83-5, (R)-3-(4-broMo-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Ruxolitinib | 5/5/2041 (Ruxolitinib) | View detail » | 2022 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/ljBpqKkrllSRpjomijniiq/591769-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/ljBpqKkrllSRpjomijniiq/591769-60-60.gif) | Cas No. 591769-05-0, 3-Cyclopentylacrylonitrile | Ruxolitinib | 5/5/2041 (Ruxolitinib) | View detail » | 2016 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lpBpqKkrllSRpjommiqpip/941685-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lpBpqKkrllSRpjommiqpip/941685-60-60.gif) | Cas No. 941685-27-4, 4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine | Ruxolitinib, Baricitinib | 5/5/2041 (Ruxolitinib); 11/30/2032 (Baricitinib) | View detail » | 2017 |
![//imrorwxhnlprli5q.ldycdn.com/cloud/lqBpqKkrllSRlknknomliq/1672665-60-60.gif](//imrorwxhnlprli5q.ldycdn.com/cloud/lqBpqKkrllSRlknknomliq/1672665-60-60.gif) | CAS No. 1672665-55-2, Benzonitrile, 3-[[2,3-dihydro-7-(methylsulfonyl)-1-oxo-1H-inden-4-yl]oxy]-5-fluoro- | Belzutifan | 9/5/2034 (Belzutifan) | View detail » | 2023 |